Specialty Area
Spotlight
Topics
Institute for Value-Based Medicine
About AJMC
Podcasts
CE
Subscribe
- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Novel Pharmacotherapies and NCCN Guideline Recommendations
Explore the evolving landscape of desmoid tumor treatments, including chemotherapy, tyrosine kinase inhibitors, and emerging clinical trials.
EP: 1.Key Background Information on Desmoid Tumors
EP: 2.Exploring the Heterogeneous Nature of Desmoid Tumors
EP: 3.The Role of Molecular Biomarkers in Diagnosing Desmoid Tumors
EP: 4.The Burden and Unmet Needs Associated with Desmoid Tumors
EP: 5.When to Observe Desmoid Tumors
EP: 6.Surgery, Cryotherapy, and Radiotherapy for Desmoid Tumors
Now Viewing
EP: 7.Novel Pharmacotherapies and NCCN Guideline Recommendations
EP: 8.Examining a Novel FDA-approved Therapy in Desmoid Tumors
Panelists discuss the questions below in this video.
- Up until a few years ago, there were no-FDA approved therapies for desmoid tumors. What was the role of chemotherapy and other pharmacotherapies like tyrosine kinase inhibitors in these patients? What is their role in current practice?
- What are the current NCCN guideline recommendations for treating desmoid tumors in patients?
- How do you utilize these in your daily practice?
- NCCN looks at surgery as a less preferred option vs. medication. How can this be incorporated into clinical practice, especially across specialties?
Related Videos
Related Content
